Start with the decisions, not the drug list

Clinical pharmacy is applied knowledge: you assess a patient, identify medicine-related problems, recommend a plan, and explain how it will be monitored. Knowing a drug’s mechanism is useful, but it is not enough. You also need to know when it is appropriate, when it is unsafe, what to check before and after starting it, and how the patient will use it.

There is no single international clinical pharmacy exam structure or syllabus. Your course, registration pathway or workplace assessment determines the exact content and format. Check the relevant university, regulator or professional body for its current requirements. The method below works across written cases, oral discussions and practice-based assessments because it organises knowledge around clinical decisions.

Use one condition at a time. Acute heart failure is a useful example because it brings together assessment, treatment goals, dose selection, monitoring, interactions and discharge counselling. The same approach can then be applied to anticoagulation, diabetes, infection, pain or other topics.

1. Define the clinical problem

Before revising treatments, write down what you need to decide. For acute heart failure, separate congestion from the longer-term treatment of heart failure with reduced ejection fraction (HFrEF). A patient who is acutely breathless and fluid-overloaded needs assessment and relief of congestion. Long-term disease-modifying medicines are a separate part of the plan, and initiation or titration depends on clinical stability and patient factors.

Build a short assessment checklist from your course material and reliable local guidance. For a case, identify the heart failure phenotype and current symptoms; review blood pressure, heart rate, volume status, renal function and potassium; and check the patient’s current medicines, allergies and adherence. Ask what could be causing deterioration, including infection, ischaemia, arrhythmia, missed doses or a medicine that worsens fluid retention.

Do not treat a laboratory value in isolation. A creatinine change, low blood pressure or raised potassium has to be interpreted with the patient’s baseline, symptoms, trend and treatment goals. In an assessment, state what information you still need rather than silently assuming it.

A MySummaries board on acute heart failure can hold the assessment and treatment notes together:

Clinical Pharmacy Acute heart failure: HFrEF medicinesStudy
Cardiology — assessment, treatment and monitoringAcute heart failure: HFrEF medicines5 sections · 3 columns
First define the problem
  • Separate congestion from chronic disease modification
  • Confirm ejection fraction, symptoms, volume status and haemodynamic stability
  • Look for triggers: infection, ischaemia, arrhythmia, missed medicines or NSAID use
Monitoring and medicine risks4 due
  • Check blood pressure, renal function and potassium before and after RAAS-modifying treatment
  • MRA example: consider only when eGFR is above 30 mL/min/1.73 m² and potassium is below 5.0 mmol/L
  • NSAIDs may worsen fluid retention and renal function
Four disease-modifying groups
  • ARNI, or ACE inhibitor/ARB when ARNI is unsuitable
  • Evidence-based beta-blocker: bisoprolol, carvedilol or metoprolol succinate
  • Mineralocorticoid receptor antagonist (MRA) and an SGLT2 inhibitor
Congestion and discharge
  • Use a loop diuretic for congestion; individualise dose to response and prior exposure
  • Check symptoms, weight, urine response, renal function and electrolytes during diuresis
  • Reconcile medicines and agree follow-up, monitoring and a clear action plan
Start and titrate safely
  • Start or increase beta-blocker when clinically stable, not during shock or worsening decompensation
  • Typical adult starting examples: bisoprolol 1.25 mg once daily; carvedilol 3.125 mg twice daily
  • Sacubitril/valsartan needs a 36-hour washout after an ACE inhibitor

2. Learn each treatment as a decision

For every medicine or class, make a compact entry with six prompts: indication, expected benefit, starting approach, important exclusions or cautions, monitoring, and counselling. This prevents revision from becoming a set of disconnected drug facts.

For HFrEF, learn the four disease-modifying groups together: an angiotensin receptor–neprilysin inhibitor (ARNI), or an ACE inhibitor/ARB where appropriate; an evidence-based beta-blocker; an MRA; and an SGLT2 inhibitor. The choice and sequence depend on the patient, local guidance and available medicines. Dapagliflozin 10 mg once daily is a commonly used HFrEF dose, but eligibility and renal thresholds differ between guidance and product information. Check the current local source rather than memorising one threshold for every setting.

A useful clinical answer links the plan to its purpose. For example: “I would review whether an ARNI is suitable for this patient, check blood pressure, renal function and potassium, and ensure there has been a 36-hour washout after an ACE inhibitor before starting sacubitril/valsartan.” That is more useful than reciting the drug name alone.

Use a short “must not miss” checklist before attempting cases. Keep it to decisions that would change safety or treatment, and verify doses and thresholds against current local guidance.

A MySummaries core checklist for this board could look like this:

Key pointsAcute heart failure: HFrEF medicines
HFrEF disease-modifying groups: ARNI (or ACE inhibitor/ARB), evidence-based beta-blocker, MRA and SGLT2 inhibitor
Allow 36 hours between stopping an ACE inhibitor and starting sacubitril/valsartan
Before MRA treatment, check potassium and renal function; a commonly used threshold is potassium <5.0 mmol/L and eGFR >30 mL/min/1.73 m²
Do not start or up-titrate a beta-blocker during shock or worsening acute decompensation; wait for clinical stability
For congestion, individualise loop-diuretic dosing and monitor symptoms, renal function and electrolytes

3. Practise monitoring and patient-specific changes

The same treatment can be suitable for one patient and unsafe for another. Practise adapting the plan to changes in renal function, potassium, blood pressure, heart rate, volume status, frailty, pregnancy potential, allergies and current medicines. Ask yourself: what is the risk, what would I check, and what change would I make if the result is abnormal?

For example, a patient taking an ACE inhibitor who is being considered for sacubitril/valsartan needs the washout period to reduce the risk of angioedema. A patient with worsening renal function or hyperkalaemia needs a review of medicines affecting renal function and potassium, not an automatic instruction to stop every heart failure treatment. The next step depends on severity, trend and clinical context; use local protocols and escalate urgent concerns appropriately.

Build spaced-repetition cards from facts that are easy to confuse: the ACE inhibitor washout, the usual MRA safety thresholds, which beta-blockers have evidence in HFrEF, and which parameters need monitoring. Answer each card before revealing it, then grade it honestly: again if you could not retrieve it, hard if recall was slow, good if correct with effort, or easy if immediate. A card should test one fact, not a whole treatment plan.

A MySummaries card drill from this board might include:

Cards — Acute heart failure: HFrEF medicines6 due

How long should a patient wait after stopping an ACE inhibitor before starting sacubitril/valsartan?

36 hours.

All 6 cards
How long should a patient wait after stopping an ACE inhibitor before starting sacubitril/valsartan?36 hours.
Name the four disease-modifying medicine groups used in HFrEF.ARNI (or ACE inhibitor/ARB), evidence-based beta-blocker, MRA and SGLT2 inhibitor.
What are commonly used potassium and eGFR thresholds for considering an MRA in HFrEF?Potassium below 5.0 mmol/L and eGFR above 30 mL/min/1.73 m²; check current local guidance.
Give one evidence-based beta-blocker used in HFrEF.Bisoprolol, carvedilol or metoprolol succinate.
When should beta-blocker initiation or up-titration be deferred in acute heart failure?During cardiogenic shock or worsening acute decompensation; wait until the patient is clinically stable.
What should be monitored when a loop diuretic is used for congestion?Clinical response and volume status, renal function and electrolytes; tailor monitoring to the patient and local protocol.

That is a MySummaries deck, filled with clinical pharmacy material. Yours is written from your own notes. Start free

4. Work through cases in a consistent order

A reliable case method keeps your answer clear under time pressure:

  1. Summarise the problem. State the likely clinical issue and any immediate safety concern.
  2. Identify missing information. Ask for relevant observations, laboratory results, history or medicine details.
  3. Set a treatment goal. For example, relieve congestion while avoiding avoidable renal or electrolyte harm.
  4. Recommend a plan. Name the medicine or change, explain why it fits, and make the dose specific only when the case and source support it.
  5. Specify monitoring and follow-up. Say what to check, when to check it according to the applicable protocol, and what would prompt reassessment.
  6. Include the patient. Explain the purpose, important use instructions and what symptoms or problems should lead the patient to seek help.

Do not give a standard dose just to sound decisive. If the case lacks information needed to dose safely, say what you need and why. In real practice, use the relevant guideline, formulary, product information and supervisory or specialist support. For study, note the source and date beside high-risk thresholds so you know when to recheck them.

5. Turn missed marks into the next study task

After a written case or oral practice, classify each omission. Was it a knowledge gap, a monitoring detail you forgot, an unsafe assumption, or an answer that was correct but too vague? Fix the specific problem. If you omitted the 36-hour washout twice, make a recall card. If you named a treatment but did not explain how you would monitor it, practise a short case answer that includes the parameter and rationale.

Use a weekly cycle: review due cards; study one condition using the six prompts; answer a patient case without notes; check your answer against current course or clinical sources; then add only the missed facts to your revision material. Keep a short error log with the error, the corrected decision and the next practice date. This gives you a concrete way to revisit weak areas instead of repeatedly rereading familiar sections.

Audio can help with concise case reasoning. Listen to a short explanation, pause after the case is presented, and say your own assessment and plan aloud before continuing. Then check whether you included the indication, safety checks, monitoring and patient advice. Listening is a supplement to retrieval and case practice, not a replacement for them.

A MySummaries lecture generated from the heart failure board might revisit the washout and monitoring decisions:

Lecture — Acute heart failure: HFrEF medicines10 min
From congestion to a safer HFrEF planMoves from the acute problem to disease-modifying treatment, monitoring and discharge checks.
04:3210:04
Speed1×1.25×1.5×2×

Transcript · tap any word to jump there

Start by separating two questions: does this patient need treatment for congestion now, and what disease-modifying treatment is appropriate once the patient is stable? A loop diuretic may be used to relieve congestion, with the dose guided by prior exposure and clinical response. Review symptoms, volume status, renal function and electrolytes; the plan is not complete if it says only ‘give a diuretic’. For HFrEF, organise the longer-term medicines into four groups: an ARNI, or an ACE inhibitor or ARB when appropriate; an evidence-based beta-blocker; an MRA; and an SGLT2 inhibitor. Check the patient’s current treatment and clinical stability before recommending a change. Do not initiate or increase a beta-blocker during shock or worsening acute decompensation.

Before starting sacubitril/valsartan, allow 36 hours after the last ACE inhibitor dose. For an MRA, assess renal function and potassium; commonly used thresholds are eGFR above 30 millilitres per minute per 1.73 square metres and potassium below 5.0 millimoles per litre, but confirm the applicable local guidance. State what you will monitor after a change and when, using the local protocol and the patient’s risk. Finally, reconcile the discharge medicines and make the follow-up plan clear to the patient and care team.

How MySummaries helps

MySummaries lets you build a revision board from your own clinical pharmacy notes, then use that board for flashcards, written cases and spoken practice. For this topic, keep your local heart failure guidance beside the board, turn the safety thresholds into cards, and use practice answers to identify which monitoring or counselling steps you are still missing.